Healthcare, AI and Consumer Stocks Under Review

Across equity markets, investors are reassessing growth, valuation and defensiveness as new data arrive on companies spanning AI infrastructure, software, healthcare and consumer staples. Recent reports highlight how differing business models and sector dynamics are shaping sentiment toward names including VNET Group, CVS Pharmacy, Nutanix, monday.com and several large-cap healthcare and consumer stocks.

VNET Group has drawn renewed attention after filings in late March 2026 showed Discovery Capital Management sharply lifting its stake, coinciding with the company’s report of a record 404 MW of data center capacity delivered in 2025. Management cited strong AI-driven demand, especially for high-performance, liquid-cooled wholesale facilities, and guided 2026 revenue to RMB 11,500–11,800 million versus reported 2025 sales of RMB 9,949.26 million.

Soon after, a Goldman Sachs (GS) report on rising short interest in Chinese data center names refocused investors on VNET’s high debt load, significant 2025–2027 maturities and refinancing risk. While narratives project CN¥14.2 billion revenue and CN¥484.1 million earnings by 2028, requiring roughly 12.5% annual revenue growth, ongoing losses and leverage concerns have kept execution risk at the center of the investment debate as the stock trades below an illustrative $14.92 fair value estimate.

Nutanix shares have been volatile, with an 8.0% one-day gain and a 4.2% seven-day rise contrasting with a 90-day decline of 18.8% and a 36.6% drop over one year at a share price of US$41.10. Against revenue of US$2.69 billion and net income of US$267.13 million, one narrative framework pegs fair value at about US$56.29, implying Nutanix is materially undervalued if earnings rise toward analyst expectations of US$544.9 million by around March 2029.

monday.com, by contrast, has faced a sharp reset, with the stock down 52.3% year to date, 70.7% over one year and 49.0% over three years, closing at US$68.34. A discounted cash flow model estimates intrinsic value of about US$149.02 per share, a 54.1% premium to the latest price, but a separate P/E-based “Fair Ratio” of 21.62x versus the current 29.22x suggests overvaluation on that metric, underscoring how different valuation approaches are yielding conflicting signals.

In medical technology, Medtronic (MDT), Intuitive Surgical (ISRG) and Boston Scientific are being viewed through both growth and defensive lenses. A discounted cash flow analysis values Medtronic (MDT) at US$93.72 per share versus a recent US$86.63, implying a modest discount. Medtronic (MDT) trades on a P/E of 24.1x, below both the Medical Equipment industry average and a company-specific Fair Ratio of 34.0x, which one framework interprets as underpricing relative to its earnings profile and risk characteristics.

Intuitive Surgical (ISRG) continues to dominate robotic-assisted surgery through its da Vinci systems, using a razor-and-blade model of capital equipment, instruments and services. Procedure growth and an installed base-led moat underpin its position, as hospitals seek minimally invasive options that can reduce complications and lengths of stay. Boston Scientific, with strengths in cardiology and endoscopy, leverages less-invasive therapies and a broad product portfolio to tap demand for minimally invasive procedures, supported by substantial R&D investment and a sizable U.S. revenue base.

CVS Pharmacy is advancing its digital health strategy, enhancing its CVS Health app with AI-driven symptom checkers, streamlined telehealth bookings and virtual consultations tied to MinuteClinic locations. With more than 9,000 retail sites and over 1,100 MinuteClinics, CVS’s mix of accessible care, prescription services and HealthHUB wellness formats is positioned as a relatively resilient healthcare and consumer staple offering amid recent market volatility.

Merck & Co. remains a major pharmaceutical name, with blockbuster drugs such as Keytruda in oncology and Gardasil vaccines anchoring revenue alongside animal health products. The company emphasizes a diversified pipeline, significant R&D spending and a long record of dividend growth, which contribute to its appeal for North American investors seeking defensive exposure to global healthcare demand.

International Flavors & Fragrances operates across taste, scent and health & biosciences, supplying customized ingredients for food, beverages and personal care. Its scale, innovation focus and U.S.-centric revenue base underpin its role as a specialty chemicals holding, even as raw material volatility, integration costs and margin pressures require monitoring. In consumer staples, Altria (MO) continues shifting from combustibles toward smoke-free products, highlighted by the nationwide rollout of On! PLUS nicotine pouches via its Helix subsidiary after expedited FDA review, while maintaining a high dividend payout backed by its Marlboro-led U.S. cigarette franchise.